TY  - JOUR
AU  - Forero‐Castro, Maribel
AU  - Robledo, Cristina
AU  - Lumbreras, Eva
AU  - Benito, Rocio
AU  - Hernández‐Sánchez, Jesús M.
AU  - Hernández Sánchez, María
AU  - García, Juan L.
AU  - Corchete‐Sánchez, Luis A.
AU  - Tormo, Mar
AU  - Barba, Pere
AU  - Menárguez Palanca, Francisco Javier
AU  - Ribera, Jordi
AU  - Grande, Carlos
AU  - Escoda, Lourdes
AU  - Olivier, Carmen
AU  - Carrillo, Estrella
AU  - García de Coca, Alfonso
AU  - Ribera, Josep‐María
AU  - Hernández‐Rivas, Jesús M.
PY  - 2016
DO  - 10.1111/bjh.13849
SN  - 0007-1048
UR  - https://hdl.handle.net/20.500.14352/93287
T2  - British Journal of Haematology
AB  - The introduction of Rituximab has improved the outcome and survivalrates of Burkitt lymphoma (BL). However, early relapse and refractorinessare current limitations of BL treatment and new biological factors affectingthe outcome of these patients have...
LA  - eng
M2  - 428
PB  - John Wiley & Sons Ltd
KW  - Burkitt lymphoma
KW  - rituximab
KW  - array-based comparative genomic hybridization (aCGH)
KW  - next-generation sequencing
KW  - outcome
TI  - The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose‐intensive chemotherapy including rituximab
TY  - journal article
VL  - 172
ER  -